Theravance Biopharma Inc
Company Profile
Business description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Contact
Ugland House, South Church Street
George Town, PO Box 309
Grand CaymanKY1-1104
CYMT: +1 650 808-6000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
99
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,316.70 | 98.30 | -1.17% |
CAC 40 | 7,274.48 | 19.89 | -0.27% |
DAX 40 | 19,884.75 | 85.11 | -0.43% |
Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
FTSE 100 | 8,084.61 | 20.71 | -0.26% |
HKSE | 19,720.70 | 31.81 | -0.16% |
NASDAQ | 19,572.60 | 199.83 | 1.03% |
Nikkei 225 | 38,701.90 | 111.68 | -0.29% |
NZX 50 Index | 12,904.11 | 149.96 | 1.18% |
S&P 500 | 5,930.85 | 63.77 | 1.09% |
S&P/ASX 200 | 8,067.00 | 101.20 | -1.24% |
SSE Composite Index | 3,368.07 | 1.96 | -0.06% |